Taxanes

Key Points

• Taxanes (for example paclitaxel, docetaxel) stabilize microtubules and block mitosis in the M phase.
• Major acute concern is hypersensitivity reaction risk; premedication is standard.
• Myelosuppression, peripheral neuropathy, GI toxicity, and alopecia are common adverse effects.
• Taxanes are generally avoided in severe baseline neutropenia (for example ANC below about 1500 cells/mm3 in solid-tumor protocols).
• Cardiac rhythm and blood-pressure changes can occur and require infusion-phase monitoring.

Mechanism of Action

Taxanes bind to microtubules and prevent normal spindle disassembly during mitosis. This blocks cell division and suppresses tumor-cell growth.

Common Drugs

• Paclitaxel
• Docetaxel

Nursing Considerations

• Verify premedication plan before infusion (commonly corticosteroid plus antihistamine, with or without H2-receptor blocker).
• Monitor for infusion and immediate post-infusion hypersensitivity signs: flushing, dyspnea, wheeze, hypotension, rash, and hemodynamic instability.
• Review CBC and neutrophil count before each cycle and hold/escalate per protocol when severe neutropenia is present.
• Trend neurologic symptoms and functional impact from peripheral neuropathy.
• Monitor for mucositis, nausea/vomiting/diarrhea, hepatotoxicity, and skin or nail changes.
• During infusion, monitor blood pressure, heart rate/rhythm, and IV site status.

Adverse Effects and Contraindications

• Hypersensitivity/anaphylaxis
• Hematologic: myelosuppression (including thrombocytopenia and neutropenia)
• Neurologic: peripheral neuropathy
• GI/mucosal: nausea, vomiting, diarrhea, mucositis
• Cardiovascular: hypotension, bradycardia, hypertension, ECG changes
• Contraindications include hypersensitivity and severe myelosuppression at baseline.

Health Teaching

• Report fever, chills, urinary symptoms, new cough, hematuria, or progressive neuropathy promptly.
• Report infusion-reaction symptoms immediately during treatment.
• Maintain hydration and follow bowel-management guidance for constipation risk.
• Avoid live vaccines and avoid new supplements/medications without oncology review.
• Continue long-term follow-up for delayed toxicity and secondary-malignancy surveillance.

Related Concepts

• antiemetics - Supportive nausea/vomiting prophylaxis and treatment.
• hematopoietic-growth-factors - Supportive management for chemotherapy-related cytopenias.
• hypersensitivity-types-and-anaphylaxis-response - Emergency recognition and treatment pathway.
• leukopenia-and-neutropenia - ANC-based risk escalation and infection prevention.

Self-Check

1. Why are premedications routinely given before many taxane infusions?
2. Which baseline lab threshold commonly guides taxane hold decisions in solid tumors?
3. What infusion-phase findings require immediate escalation for possible hypersensitivity?